Results 121 to 130 of about 95,577 (390)
Brain SciencesThe acute levodopa challenge is widely used to distinguish Parkinson’s disease (PD) from atypical parkinsonian syndromes (APSs) such as multiple system atrophy (MSA) and progressive supranuclear palsy (PSP).
Lan Ye +8 more
doaj +1 more source
A randomized trial of inhaled levodopa (CVT‐301) for motor fluctuations in Parkinson's disease
Movement Disorders, 2016 Although levodopa is the most effective oral PD therapy, many patients experience motor fluctuations, including sudden loss of dose effect and delayed benefit. CVT‐301 is a levodopa inhalation powder with the potential for rapid onset of action.
P. LeWitt +10 more
semanticscholar +1 more source
Movement Disorders Clinical Practice, EarlyView.Abstract Background Levodopa–entacapone–carbidopa intestinal gel (LECIG) was introduced in 2018 as a device‐aided therapy for advanced Parkinson's disease (PD). Objectives The ELEGANCE study (NCT05043103) is gathering real‐world data on long‐term efficacy, safety and patient‐reported outcomes with LECIG from 13 European countries.
Daniel Weiss +10 more
wiley +1 more source
Neurobiology of Disease, 2016 Ras homolog enriched in striatum (Rhes) is a small GTP-binding protein that modulates signal transduction at dopamine receptors, and also activates mammalian target of rapamycin complex 1 (mTORC1). Rhes binding to mTORC1 is hypothesized to play a role in
Alberto Brugnoli +3 more
doaj
Effect of levodopa‐carbidopa intestinal gel on dyskinesia in advanced Parkinson's disease patients
Movement Disorders, 2016 The purpose of this study was to assess the effect of levodopa‐carbidopa intestinal gel (carbidopa‐levodopa enteral suspension) in advanced Parkinson's disease patients with troublesome dyskinesia.
A. Antonini +7 more
semanticscholar +1 more source
Altered intrinsic functional coupling between core neurocognitive networks in Parkinson\u27s disease [PDF]
, 2015 Parkinson3s disease (PD) is largely attributed to disruptions in the nigrostriatal dopamine system. These neurodegenerative changes may also have a more global effect on intrinsic brain organization at the cortical level.
Cronin-Golomb, Alice +4 more
core +1 more source
Catechol-O-methyltransferase inhibition with tolcapone reduces the "wearing off" phenomenon and levodopa requirements in fluctuating parkinsonian patients. [PDF]
, 1997 BACKGROUND: More than 50% of patients with Parkinson's disease develop motor response fluctuations (the "wearing off" phenomenon) after more than five years of levodopa therapy.
Baas, H. +6 more
core +1 more source
Pharmacokinetics and safety/efficacy of levodopa pro-drug ONO-2160/carbidopa for Parkinson's disease
eNeurologicalSci, 2018 We conducted a phase I study investigating the efficacy, safety, and tolerability of ONO-2160, a newly developed levodopa pro-drug, and carbidopa compared with levodopa and carbidopa to stabilize levodopa plasma concentration fluctuations in Japanese ...
Masahiro Nomoto +7 more
doaj
Action of Thymoxamine on Mydriasis induced by Levodopa and Dopamine [PDF]
, 1971 A. S. D. Spiers +3 more
openalex +1 more source
Brain and Behavior, 2017 To determine the possible interactions between levodopa therapy and plasma levels of B vitamins in patients with advanced idiopathic Parkinson's disease (IPD) in the context of either oral levodopa therapy or levodopa/carbidopa intestinal gel (LCIG ...
Sebastian Loens +4 more
semanticscholar +1 more source